TCEs are bispecific antibody-based therapies designed to address the challenge of tumor cells downregulating MHC expression, a common mechanism of immune evasion that disrupts T-cell-mediated antitumor activity [31,32]. This evidence concerns the gene HLA-C and neoplasm.